Prostate Cancer News on BioPortfolio

Pfizer's Xtandi delays prostate cancer spread in early stage disease

Reuters Use of Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone study results that could lead to significantly increased sales of the...

PSMA PETCT clearly differentiates prostate cancer from benign tissue

Society of Nuclear Medicine and Molecular Imaging Using nuclear medicine German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of ...

Pages